BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: A 19-week, phase ii, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. Clinical Therapeutics 2007;29:626-39. [DOI: 10.1016/j.clinthera.2007.04.014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Guan F, Uboh CE, Soma LR, Maylin G, Jiang Z, Chen J. Confirmatory Analysis of Continuous Erythropoietin Receptor Activator and Erythropoietin Analogues in Equine Plasma by LC−MS for Doping Control. Anal Chem 2010;82:9074-81. [DOI: 10.1021/ac102031w] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
2 Washida N, Inoue S, Kasai T, Shinozuka K, Hosoya K, Morimoto K, Wakino S, Hayashi K, Itoh H. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients: Switching from Darbepoietin Alfa to Epoetin Beta Pegol. Ther Apher Dial 2015;19:450-6. [DOI: 10.1111/1744-9987.12306] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Joré C, Brun JF, Varlet-Marie E. Rise in RBC aggregability and concomitant decrease in blood pressure 10 days after injection of the long acting erythropoietin analogue methoxy polyethylene glycol-epoetin-β (MIRCERA®). Clin Hemorheol Microcirc 2016;64:809-16. [PMID: 27767968 DOI: 10.3233/CH-168015] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Cody J, Daly C, Campbell M, Donaldson C, Khan I, Rabindranath K, Vale L, Wallace S, Macleod A. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 2005;:CD003266. [PMID: 16034896 DOI: 10.1002/14651858.CD003266.pub2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
5 Ikenoue T, Naito H, Kitamura T, Hattori H. Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: a case report. J Med Case Rep 2017;11:296. [PMID: 29047386 DOI: 10.1186/s13256-017-1468-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
6 Schmidt RJ. Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off? Expert Opinion on Pharmacotherapy 2009;10:1509-14. [DOI: 10.1517/14656560902997982] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Locatelli F, Reigner B. C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease. Expert Opinion on Investigational Drugs 2007;16:1649-61. [DOI: 10.1517/13543784.16.10.1649] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
8 Ohashi N, Sakao Y, Yasuda H, Kato A, Fujigaki Y. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis 2012;5:53-60. [PMID: 22536082 DOI: 10.2147/IJNRD.S23447] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Alsalimy N, Awaisu A. Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review. Int J Clin Pharm 2014;36:1115-25. [DOI: 10.1007/s11096-014-0023-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
10 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
11 Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U. C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks. Am J Nephrol 2008;28:280-9. [DOI: 10.1159/000111115] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
12 Topf JM. CERA: third-generation erythropoiesis-stimulating agent. Expert Opin Pharmacother 2008;9:839-49. [PMID: 18345959 DOI: 10.1517/14656566.9.5.839] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
13 Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus®) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol 2021; 10(6): 109-121 [PMID: 34909408 DOI: 10.5527/wjn.v10.i6.109] [Reference Citation Analysis]
14 Scarth JP, Seibert C, Brown PR, Teale P, Beamon GJ, Pearce CM, Sams RA. UPLC-MS/MS Method for the Identification of Recombinant Human Erythropoietin Analogues in Horse Plasma and Urine. Chromatographia 2011;74:593-608. [DOI: 10.1007/s10337-011-2119-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
15 Pirkle JL Jr, Paoli CJ, Russell G, Petersen J, Burkart J. Hemoglobin stability and patient compliance with darbepoetin alfa in peritoneal dialysis patients after the implementation of the prospective payment system. Clin Ther 2014;36:1665-74. [PMID: 25256386 DOI: 10.1016/j.clinthera.2014.08.011] [Reference Citation Analysis]
16 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
17 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
18 Levin NW, Fishbane S, Cañedo FV, Zeig S, Nassar GM, Moran JE, Villa G, Beyer U, Oguey D. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). The Lancet 2007;370:1415-21. [DOI: 10.1016/s0140-6736(07)61599-2] [Cited by in Crossref: 109] [Cited by in F6Publishing: 36] [Article Influence: 7.3] [Reference Citation Analysis]
19 Ebbers HC, Muenzberg M, Schellekens H. The safety of switching between therapeutic proteins. Expert Opin Biol Ther. 2012;12:1473-1485. [PMID: 22849511 DOI: 10.1517/14712598.2012.711308] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
20 Schmid H. Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure. Expert Rev Hematol 2016;9:5-20. [PMID: 26573694 DOI: 10.1586/17474086.2016.1112734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
21 Arikan H, Asicioglu E, Velioglu A, Nalcaci S, Birdal G, Guler D, Koc M, Tuglular S, Ozener C. Determinants of hemoglobin variability in stable peritoneal dialysis patients. Int Urol Nephrol 2014;46:1427-34. [PMID: 24687636 DOI: 10.1007/s11255-014-0700-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Üstündağ S, Doğan E, Duranay M, Kazancıoğlu R, Çelik V, Ünsal A, Altıntepe L, Dursun B, Akbaş E, Özdener F, Yıldız A. Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Predialysis Patients. Balkan Med J 2016;33:322-30. [PMID: 27308077 DOI: 10.5152/balkanmedj.2016.141173] [Reference Citation Analysis]
23 Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-80. [PMID: 20706990 DOI: 10.1002/ajh.21805] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
24 Locatelli F, Covic A, Eckardt K, Wiecek A, Vanholder R; on behalf of the ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2008;24:348-54. [DOI: 10.1093/ndt/gfn653] [Cited by in Crossref: 129] [Cited by in F6Publishing: 94] [Article Influence: 9.2] [Reference Citation Analysis]
25 Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, Locatelli F, Dougherty FC, Beyer U; ARCTOS Study Investigators. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. Clin J Am Soc Nephrol 2008;3:337-47. [PMID: 18287255 DOI: 10.2215/CJN.00480107] [Cited by in Crossref: 68] [Cited by in F6Publishing: 27] [Article Influence: 4.9] [Reference Citation Analysis]
26 Frimat L, Mariat C, Landais P, Koné S, Commenges B, Choukroun G. Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis. BMJ Open 2013;3:e001888. [PMID: 23474787 DOI: 10.1136/bmjopen-2012-001888] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
27 Selby NM, Fonseca SA, Fluck RJ, Taal MW. Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis. Perit Dial Int 2012;32:177-82. [PMID: 22045101 DOI: 10.3747/pdi.2010.00299] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
28 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
29 Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U. Efficacy of Intravenous Methoxy Polyethylene Glycol-Epoetin Beta Administered Every 2 Weeks Compared With Epoetin Administered 3 Times Weekly in Patients Treated by Hemodialysis or Peritoneal Dialysis: A Randomized Trial. American Journal of Kidney Diseases 2007;50:989-1000. [DOI: 10.1053/j.ajkd.2007.08.013] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
30 Kalantar-Zadeh K, Aronoff GR. Hemoglobin variability in anemia of chronic kidney disease. J Am Soc Nephrol 2009;20:479-87. [PMID: 19211716 DOI: 10.1681/ASN.2007070728] [Cited by in Crossref: 64] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]